Income before deduction of interest, taxes and amortization: SELLAS Life Sciences (SLS)
Production automation and AI-driven drug modeling are creating financial pressure, which is evident in the EBITDA growth trajectory displayed on GURU.Markets; meanwhile, the value of 0.00 reflects the metric's balance. Patents and vaccine royalties provide stability, yet the survival of SELLAS Life Sciences (SLS) currently depends on the results of Phase III leukemia trials due to a critical decline in capital.
Summary analytical data breakdowns for SELLAS Life Sciences Group (SLS)
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- book capitalization information:
- business debt structure and liquidity details:
Debt to Capital SELLAS Life Sciences|SLS - Long-Term Debt to Equity|Short-Term Debt to Equity SELLAS Life Sciences Group, Inc.|SLS - Company Debts|Debt to Book Capitalization Ratio SELLAS Life Sciences|SLS - Company Long-Term Debts|Company Short-Term Debts SELLAS Life Sciences|Interim Coverage Ratio sellaslifesciences.com
- earnings and market multiples details:
SLS - Net Income|Expected Net Income SELLAS Life Sciences|SLS - Price to Earnings Ratio|Future Price to Earnings SELLAS Life Sciences Group, Inc.|SLS - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio SELLAS Life Sciences|SLS - Operating profit EBITDA|Earnings per one share for the last 12 months SELLAS Life Sciences|SLS - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months sellaslifesciences.com|SLS - Net earnings per share growth this year|Expected earnings per share trend next year SELLAS Life Sciences
Analysis of all company metrics:SELLAS Life Sciences (SLS)
For SELLAS Life Sciences (SLS), which is developing alliances with oncology centers to create immunotherapeutic vaccines, the projected EBITDA level serves as an indicator of operational management efficiency. This metric reflects cash flow before depreciation and interest, allowing investors to assess the business's actual ability to generate cash and determine capital stability through the analysis of historical extremes without the risk of overpaying for the asset.
Who SELLAS Life Sciences competes with
Operating profit EBITDA BeiGene Oncology ONC|HALO - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization RVMD (revmed.com)|AAPG: Operating profit EBITDA|Profit before interest, taxes and amortization CG Oncology Inc (CGON)|Profit before payment of interest, taxes and amortization UroGen|Bicara Corp (BCAX) - Operating income before deduction of amortization|Operating profit EBITDA PSNL|ERAS - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Delcath Systems DCTH|Y-mAbs Therapeutics Inc - Profit before payment of interest, taxes and amortization|AURA - Profit before payment of interest, taxes and amortization|CADL: Profit before payment of interest, taxes and amortization|ARAY: Operating profit EBITDA|actuatetherapeutics.com (ACTU) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Citius Oncology|TuHURA (HURA) - Operating income before deduction of amortization|Operating profit before deduction of amortization TARA (Protara)|FATE (Fate Pharma) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Aadi Bioscience WHWK|TScan Therapeutics Inc - Profit before payment of interest, taxes and amortization|Champions Oncology Corp - Operating profit EBITDA|Operating income before deduction of amortization XBiotech Inc. XBIT|CVM: Operating profit EBITDA|Profit before deduction of interest, taxes, depreciation and amortization OSTX (OS Therapies, Inc.)|RADX (Radiopharm Theranostics) - Operating profit EBITDA|Profit before interest, taxes and amortization Artiva ARTV|Operating profit before deduction of amortization ANL (Adlai Nortye Ltd.)|VERU (Veru Inc) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Tempest Tx TPST|Operating income before deduction of amortization Xilio Therapeutics Inc (XLO)|Enochian BioSciences - Operating profit EBITDA|Mural Oncology plc (MURA) - Operating profit before deduction of amortization|KAPA: Operating profit EBITDA|OKUR - Operating income before deduction of amortization|GDTC (CytoMed Therapeutics Ltd) - Operating profit EBITDA|Profit before interest, taxes and amortization Curis Corp CRIS|Profit before payment of interest, taxes and amortization Apollomics, Inc. (APLM)|tharimmune.com - Operating profit before amortization|Operating profit EBITDA ADVB (Advanced Biomed)|GNPX - Operating profit before deduction of amortization|Calidi Bio - Operating profit EBITDA|Profit before interest, taxes and amortization sunshinebiopharma.com|xeneticbio.com (XBIO) - Profit before payment of interest, taxes and amortization|SLRX - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Purple Biotech Ltd.|AON (AONC) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization BeOne Medicines (BGNE)|Profit before payment of interest, taxes and amortization CKPT (Checkpoint Therapeutics Inc)|Profit before payment of interest, taxes and amortization Elevation Oncology ELEV|Operating income before deduction of amortization iCAD Inc. (ICAD)|Ikena - Operating profit EBITDA|Notable Labs Ltd (NTBL) - Operating profit before deduction of amortization|VIRX: Operating profit EBITDA|MorphoSys Corporation (MOR) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization NAYA Biosciences|Operating profit before amortization AAPGV (ascentage.com)
